CERo Therapeutics Hldgs Bolsa (NASDAQ: CERO)

Últimas noticias sobre CERo Therapeutics Hldgs (NASDAQ:CERO) Bolsa

CERo Therapeutics Hldgs

CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.

Earnings

News

Markets

Trading Ideas

APDN

AUID

CERO

COMM

CRVS

EFSH

FSBW

NIVF

NUKK

PRTG

PRZO

PTPI

RZLV

SHLT

SSBK

TNXP

VSTE

Acciones de Corvus suben un 22,5% pre-market tras anunciar datos de Soquelitinib. Descubre más ganadores y perdedores.

Acciones de Corvus Pharmaceuticals (CRVS) suben alrededor del 22%; 20 acciones que se mueven en premercado

CERo Therapeutics Holdings, Inc. - Common Stock

CERo Therapeutics Holdings Inc

CERo Therapeutics Holdings, Inc. - Warrants

CERO THERAPEUTICS HOLDINGS INC UNIT 1 CL A & 1/3 WT EXP

CoStar Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSGP#NASDAQ">CSGP</a>) has outperformed the market over the past 20 years by 7.51% on an annualized basis producing an average annual return of 15.83%. Currently, CoStar Group has a market capitalization of $32.08 billion. 
Buying $1000 In CSGP: If an investor had bought $1000 of CSGP stock 20 years ago, it would be worth $19,117.65 today based on a price of $76.05 for CSGP at the time of writing.
<h3>CoStar Group's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747350911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CSGP

Here's How Much $1000 Invested In CoStar Group 20 Years Ago Would Be Worth Today

Gold rush is back, and instead of miners and pickaxes, its hedge funds and billion-dollar spreadsheets. 
Ray Dalio&#8217;s Bridgewater Associates <a href="https://www.benzinga.com/hedge-funds/25/05/45447966/ray-dalios-bridgewater-dumps-spy-trims-nvidia-meta-alphabet-bearish-vibes">opened a fresh $318.8 million position</a> in SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) during the first quarter of 2025, as per a new 13F filing with the SEC. For the world&#8217;s largest hedge fund, it&#8217;s not mere portfolio adjustment, it&#8217;s a shiny declaration.
Dalio, a long-time outspoken proponent of &#8220;hard money,&#8221; recently doubled down on his opinion during a presentation at Abu Dhabi Finance Week. Forecasting a coming &#8220;debt money problem&#8221; due to hyperborrowing by the U.S., China and virtually every large economy other than Germany, Dalio expressed his fondness for the likes of gold and Bitcoin over conventional debt vehicles.
Also Read: <a href="https://www.benzinga.com/etfs/specialty-etfs/25/05/45235676/exclusive-expert-explains-how-this-gold-etf-lets-you-physically-hold-your-wealth-and-why-investors-are-quietly-rushing-in">Exclusive: Expert Explains How This Gold ETF Lets You Physically Hold Your Wealth And Why Investors Are Quietly Rushing In</a>
He&#8217;s not the only one embracing this golden gospel. No, institutional investors are flocking to the yellow metal at a furious clip — 1,187 GLD shares were added last quarter. BlackRock, Goldman Sachs and UBS all bulled up their gold ETFs with positions in GLD, according to Quiver Quantitative.
<h1 class="wp-block-heading">GLD Is The Standard-Bearer—But Not The Only Game In Town</h1>
GLD might be the <a href="https://www.benzinga.com/etfs">gold ETF heavyweight</a> champion, but it&#8217;s not alone in the ring. Those interested in playing with bullion without keeping it under the mattress can consider:
iShares Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAU#NYSE">IAU</a>): Inexpensive and popular with good liquidity, perfect for long-term investors who prefer fees on the lean side (expense ratio is 0.25%).
SPDR Gold MiniShares Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLDM#NYSE">GLDM</a>): It&#8217;s like GLD&#8217;s less expensive cousin and it has a smaller expense ratio (0.1%).
Goldman Sachs Physical Gold ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/AAAU#BATS">AAAU</a>): Supported by physical gold and Goldman&#8217;s influence, it&#8217;s picking up among newer gold bugs.
<h2 class="wp-block-heading">The Golden Fuel</h2>
Aside from hedge fund mania, there is a macro muscle driving the gold rally. Central banks have purchased more than 1,000 metric tons of gold per year since Russia&#8217;s invasion of Ukraine in 2022, twice the amount of the previous decade, per a Reuters report from April. 
Why? Central banks are diversifying out of the dollar and hedging against geopolitical risk and Trump-fiscal pyrotechnics.
<h1 class="wp-block-heading">The Bigger Picture</h1>
Dalio puts it best: debt, money and the economy are only one of five epic forces remaking the world. The others — domestic political strains, foreign geopolitical conflicts, acts of nature, and technological innovation — are all lighting up red or amber. Gold, in such a scenario, is not simply a safety net. It&#8217;s a statement.
So, whether you're a hedge fund titan, a cautious retail investor or someone who just likes a little shine in their portfolio, the message is clear: in an age of debt and disruption, gold isn't going out of style anytime soon.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/05/45448912/lazard-transforms-mutual-fund-into-ieq-etf-amid-rising-demand-for-international-stocks">Lazard Transforms Mutual Fund Into IEQ ETF Amid Rising Demand For International Stocks</a></li>
</ul>
Photo: Shutterstock

Specialty ETFs

Commodities

ETFs

AAAU

GLDM

Move Over Miners, Hedge Funds Are The New Gold Diggers ... Ray Dalio, BlackRock, Goldman Sachs, Others Stake Claims In GLD

The Port of Los Angeles, the busiest in the Western Hemisphere, has seen a 35% drop in cargo volume compared to the same period last year, according to Gene Seroka, the port&#8217;s executive director. The drop reflects the harsh impact of recent tariffs imposed by President Donald Trump&#8217;s administration.&nbsp;
<h2 class="wp-block-heading">Pushback on Fox News</h2>
The economic fallout from these tariffs sparked a heated exchange on the recent Fox News &#8220;The Five&#8221; <a href="https://x.com/JessicaTarlov/status/1920159291530485767">show</a>. One of the hosts, Jessica Tarlov, argued that despite the administration&#8217;s attempts to downplay the impact, the consequences are already being felt.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The executive director of the port of Los Angeles talked about how the port is now down 35% in terms of volume. He says truckers and dockworkers are going to be laid off. It&#39;s incredible the Trump Administration is acting like this isn't a big deal. <a href="https://t.co/wOt3ADHHtq">pic.twitter.com/wOt3ADHHtq</a>
&mdash; Jessica Tarlov (@JessicaTarlov) <a href="https://twitter.com/JessicaTarlov/status/1920159291530485767?ref_src=twsrc%5Etfw">May 7, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Don't Miss:
<ul class="wp-block-list">
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.30/share with a $1000 minimum.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">Invest before it's too late.</a></li>
</ul>
&#8220;Prices are already going up,&#8221; Tarlov said, highlighting layoffs at a Mack truck plant in Pennsylvania and rising costs hitting major companies like Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) and Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>). She pointed to the executive director of the Port of Los Angeles, who, besides reporting a 35% drop in cargo volume, also warned that truckers and dock workers could soon face significant layoffs.
When co-hosts Jeanine Pirro and Greg Gutfeld tried to push back, suggesting that there&#8217;s always talk about layoffs but they never happen, Tarlov shot back, &#8220;It&#8217;s <a href="https://www.benzinga.com/markets/equities/25/04/44642355/trumps-25-auto-tariffs-spark-stellantis-layoffs-gm-expansion-uaws-shawn-fain-calls-job-cuts-completely-unnecessary">not true that it doesn&#8217;t happen</a>&#8230; These are real consequences.&#8221;
As she wrote in a <a href="https://x.com/JessicaTarlov/status/1920159291530485767">post on X</a> on Wednesday, &#8220;It&#8217;s incredible the Trump Administration is acting like this isn't a big deal.&#8221;
Trending: Nancy Pelosi Invested $5 Million In An AI Company Last Year — <a href="https://www.benzinga.com/money/elf-labs-ym?v=123">Here's How You Can Invest In Multiple Pre-IPO AI Startups With Just $1,000.</a>
She argued that countries are finding ways to adapt to the tariffs, noting that Canada has increased its exports to other markets by 25% since the tariffs were introduced. Co-host Jesse Watters challenged this claim, insisting that Canada&#8217;s economy is struggling, but Tarlov stood firm, saying, &#8220;I do look at the statistics all day.&#8221;
She also cited comments from Treasury Secretary Scott Bessent, who, at the time, acknowledged that the U.S. hadn&#8217;t had direct trade talks with China, despite Trump&#8217;s claims to the contrary. Tarlov noted that Bessent told Congress the administration has engaged with 17 countries about trade, but not China, which remains the critical player in the ongoing dispute.
See Also: <a href="https://www.benzinga.com/money/this-ai-imaging-technology-has-been-used-in-more-than-500-surgeries-now-you-can-be-part-of-the-ai-imaging-revolution">Be part of the next med-tech breakthrough for only $350 — 500+ surgeries already done with nView's AI system.</a>
<h2 class="wp-block-heading">Impact on Workers and Local Businesses</h2>
For workers like Charlie Camacho, a longshore worker whose family has worked at the port for three generations, the decline is already hitting home. Speaking to <a href="https://www.npr.org/2025/05/07/nx-s1-5389955/los-angeles-port-tariffs">NPR</a>, Camacho described the struggle to find work as container volumes plummet. &#8220;Less volume of cargo containers means less work for us,&#8221; he said. &#8220;We feel it, we definitely feel it.&#8221;
It&#8217;s not just dockworkers feeling the squeeze. Small business owners like Frank Groves, who sells gloves and safety gear to port workers, have also seen their income collapse. Groves told NPR that his business is down nearly 75% in recent weeks. &#8220;No sales at all really. If they aren&#8217;t working, I don&#8217;t make money,&#8221; he said.
Even if the tariffs were to be lifted soon, some experts say the damage could be long-lasting. Former Los Angeles City Harbor Commissioner Diane Middleton warned that supply chains can&#8217;t be rebuilt overnight. &#8220;You don&#8217;t just have ships lined up like taxi cabs,&#8221; she told NPR, noting that the logistical challenges of reversing these disruptions could linger for months, if not years. &#8220;You have to reserve vessels. You have to specify a time. Once you&#8217;ve cut all that off, you can&#8217;t bring it back in a minute.&#8221;
As the debate over tariffs continues, it's clear that the <a href="https://www.benzinga.com/personal-finance/25/05/45183970/behind-the-empty-docks-how-trumps-145-tariffs-are-gutting-u-s-supply-chains">economic fallout</a> is already hitting American businesses and workers hard, despite the administration&#8217;s attempts to downplay the impact.
Read Next:
<ul class="wp-block-list">
<li>Invest where it hurts — and help millions heal:<a href="https://www.benzinga.com/money/a-cure-for-osteoarthritis-powered-by-everyday-investors-cytonics-is-looking-to-beat-big-pharma-and-disrupt-a-390-billion-market"> Invest in Cytonics and help disrupt a $390B Big Pharma stronghold</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.30/share!</a></li>
</ul>
Image: Shutterstock

MSFT

'It's Incredible The Trump Administration Is Acting Like This Isn't A Big Deal,' Says Fox Host As LA Port Volume Drops 35% And Layoffs Loom

Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) has outperformed the market over the past 15 years by 4.79% on an annualized basis producing an average annual return of 16.71%. Currently, Extra Space Storage has a market capitalization of $31.53 billion. 
Buying $1000 In EXR: If an investor had bought $1000 of EXR stock 15 years ago, it would be worth $10,597.72 today based on a price of $148.58 for EXR at the time of writing.
<h3>Extra Space Storage's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747350014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

Home Depot (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HD#NYSE">HD</a>) has outperformed the market over the past 10 years by 2.2% on an annualized basis producing an average annual return of 12.94%. Currently, Home Depot has a market capitalization of $376.37 billion. 
Buying $100 In HD: If an investor had bought $100 of HD stock 10 years ago, it would be worth $337.04 today based on a price of $378.63 for HD at the time of writing.
<h3>Home Depot's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747349113_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Home Depot 10 Years Ago Would Be Worth This Much Today

Sky Quarry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYQ#NASDAQ">SKYQ</a>) reported quarterly losses of $(0.16) per share. This is a 6.67 percent decrease over losses of $(0.15) per share from the same period last year. The company reported $6.33 million in sales this quarter. This is a 42.18 percent decrease over sales of $10.95 million the same period last year.

SKYQ

Sky Quarry Q1 EPS $(0.16) Down From $(0.15) YoY, Sales $6.33M Down From $10.95M YoY

It&#8217;s been a roller coaster year for Wall Street as investors revise expectations during a period of <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45435725/tariffs-slow-retail-spending-as-producer-prices-post-sharpest-drop-since-2020">rapidly changing policy announcements</a> in the White House. While markets turned bearish in March and April as the Trump Administration threatened tariffs on several U.S. trade partners, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) retraced some of its losses as the administration backed off some of its policy commitments and <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45376487/wall-street-edges-higher-as-inflation-cools-nasdaq-100-hits-10-week-highs">economic indicators look promising</a>.
Stephanie Link, chief investment officer and portfolio manager at Hightower Advisors, is optimistic about the market&#8217;s prospects if tariff concerns can be averted.
&#8220;I think the biggest surprise is that the Atlanta Fed [GDPNow] is at 2.3% in the face of everything,&#8221; Link wrote on Thursday. &#8220;Consumer continues to spend — Walmart is proof of that. Labor market remains solid and inflation is coming down albeit slowly. EPS up 12% is impressive as well. Get through tariffs and we'll start to focus on more positive things — lower taxes and deregulation.&#8221;
Link noted two contrarian plays she is bullish on as 2025 enters its second half. She called Boeing Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) her &#8220;favorite stock for 2025&#8221; amid the company&#8217;s turnaround under new leadership. While the Arlington, Virginia-based company&#8217;s shares have fallen from all-time highs due to regulatory woes and safety concerns, its stock is up over 20% in 2025.
Link also highlighted private equity giant KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) as a firm benefiting from several positive trends.
&#8220;Added KKR this past week [with] the stock down 15% ytd and a play on growth, real assets, infrastructure and fee growth,&#8221; Link said.
She noted Quanta Services Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PWR#NYSE">PWR</a>), Eaton Corporation PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) and Rockwell Automation Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ROK#NYSE">ROK</a>) as other infrastructure plays.
Also Read:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45439079/powell-signals-fed-may-shift-its-inflation-strategy-after-5-year-economic-shake-up">Powell Signals Fed May Shift Inflation Strategy After 5 Years Of Economic Upheaval</a></li>
</ul>
Photo: Shutterstock

Equities

Hedge Funds

Exclusives

'My Favorite Stock For 2025,' Says Portfolio Manager, Who Also Notes Two Contrarian Plays During Growth Optimism

Femto Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FMTO#NASDAQ">FMTO</a>) reported quarterly losses of $(2.50 thousand) per share. The company reported $141.20 thousand in sales this quarter.

FMTO

Femto Technologies Q1 EPS $(2.50K), Sales $141.20K

Pasithea Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTTA#NASDAQ">KTTA</a>) reported quarterly losses of $(1.61) per share. This is a 56.49 percent increase over losses of $(3.70) per share from the same period last year.

KTTA

Pasithea Therapeutics Q1 EPS $(1.61) Up From $(3.70) YoY

Vincerx Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VINC#NASDAQ">VINC</a>) reported quarterly losses of $(1.40) per share. This is a 87.93 percent increase over losses of $(11.60) per share from the same period last year.

VINC

Vincerx Pharma Q1 EPS $(1.40) Up From $(11.60) YoY

HOOKIPA Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOK#NASDAQ">HOOK</a>) reported quarterly losses of $(1.23) per share which missed the analyst consensus estimate of $(0.62) by 98.39 percent. This is a 211.82 percent decrease over earnings of $1.10 per share from the same period last year. The company reported quarterly sales of $2.00 million which missed the analyst consensus estimate of $3.38 million by 40.62 percent. This is a 94.52 percent decrease over sales of $36.60 million the same period last year.

Earnings Misses

HOOK

HOOKIPA Pharma Q1 EPS $(1.23) Misses $(0.62) Estimate, Sales $2.00M Miss $3.38M Estimate

Safety Shot (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHOT#NASDAQ">SHOT</a>) reported quarterly losses of $(0.08) per share. This is a 75.76 percent increase over losses of $(0.33) per share from the same period last year. The company reported $42.10 thousand in sales this quarter. This is a 75.34 percent decrease over sales of $170.73 thousand the same period last year.

SHOT

Safety Shot Q1 EPS $(0.08) Up From $(0.33) YoY, Sales $42.10K Down From $170.73K YoY

Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) reported quarterly losses of $(1.64) per share. This is a 82.25 percent increase over losses of $(9.24) per share from the same period last year. The company reported $322.00 thousand in sales this quarter. This is a 37.23 percent decrease over sales of $513.00 thousand the same period last year.

MNTS

Momentus Q1 EPS $(1.64) Up From $(9.24) YoY, Sales $322.00K Down From $513.00K YoY

Franklin Wireless (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FKWL#NASDAQ">FKWL</a>) reported quarterly losses of $(0.05) per share. This is a 50 percent increase over losses of $(0.10) per share from the same period last year. The company reported $8.01 million in sales this quarter. This is a 29.70 percent increase over sales of $6.18 million the same period last year.

FKWL

Franklin Wireless Q3 EPS $(0.05) Up From $(0.10) YoY, Sales $8.01M Up From $6.18M YoY

GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.64) by 48.44 percent. This is a 79.88 percent increase over losses of $(1.64) per share from the same period last year.

Earnings Beats

GTBP

GT Biopharma Q1 EPS $(0.33) Beats $(0.64) Estimate

HCW Biologics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) reported quarterly losses of $(0.05) per share. This is a 75 percent increase over losses of $(0.20) per share from the same period last year. The company reported $5.07 thousand in sales this quarter. This is a 99.55 percent decrease over sales of $1.13 million the same period last year.

HCWB

HCW Biologics Q1 EPS $(0.05) Up From $(0.20) YoY, Sales $5.07K Down From $1.13M YoY

Teva Pharmaceuticals (NYSE and TASE: TEVA)&nbsp;today announced that Moody's Investor Services ("Moody's") has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Analyst Ratings

TEVA

Teva Pharmaceuticals Announced That Moody's Investor Services Has Raised The Company's Corporate Credit Rating To Ba1, Outlook Stable From Ba2, Outlook Positive

Jones Soda (OTC:<a class="ticker" href="https://www.benzinga.com/stock/JSDA#OTC">JSDA</a>) reported quarterly losses of $(0.01) per share. This is unchanged from the same period last year. The company reported $4.61 million in sales this quarter. This is a 7.82 percent decrease over sales of $5.00 million the same period last year.

JSDA

Jones Soda Q1 EPS $(0.01), Same YoY, Sales $4.61M Down From $5.00M YoY

Pioneer Power Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPSI#NASDAQ">PPSI</a>) affirms FY2025 sales outlook from $27.00 million-$29.00 million to $27.00 million-$29.00 million vs $27.79 million estimate.

Guidance

PPSI

Pioneer Power Solutions Affirms FY2025 Sales Guidance of $27.00M-$29.00M vs $27.79M Est

— Company Estimates Revenue Growth of 40%+ in Q1'25 —
— Company Reiterates Plans to Issue Final Q1'25 Results on May 20, 2025 —
Evolv Technologies Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVLV#NASDAQ">EVLV</a>), a leading security technology company pioneering AI-based solutions designed to help create safer experiences, today provided an update on its preliminary financial results for the first quarter of 2025 as well as its upcoming plans to file its related Quarterly Report on Form 10-Q with the Securities and Exchange Commission.
Company Provides Preliminary Update for First Quarter of 2025
The Company today provided an update on preliminary results for the first quarter of 2025. Based on preliminary estimates which are subject to change, the Company expects total revenue to be between approximately $31.0 million and $32.0 million, compared to total revenue of $22.2 million in the first quarter of 2024. The Company expects less than $0.1 million of revenue to be related to the restatement previously completed by the Company. As previously disclosed, as of March 31, 2025, the Company had total cash, cash equivalents, and marketable securities of $35 million, with no outstanding debt. The Company will release final financial results for the first quarter of 2025 on Tuesday, May 20, 2025, after the market closes. Members of the Company's management team plan to host a live webcast at 4:30 p.m. Eastern Time on that day to discuss the financial results as well as management's outlook for the business. The conference call will be webcast live at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fir.evolvtechnology.com&amp;esheet=54255829&amp;newsitemid=20250515290964&amp;lan=en-US&amp;anchor=http%3A%2F%2Fir.evolvtechnology.com&amp;index=1&amp;md5=e090a672c321cba1771ef1925825cbe4">http://ir.evolvtechnology.com</a>.

EVLV

Evolv Technologies Estimates 40%+ Revenue Growth Between $31M - $32M In Q1 2025, Maintains $35M In Cash With No Debt, And Will Release Final Results On May 20, 2025

Press Releases

CERo Therapeutics Holdings, Inc. Continues to Progress Toward Initial Dosing of Patients in Phase 1 Trial with Agreement with University of California Davis for Manufacturing Services

CERo Therapeutics Holdings, Inc.  Poised to Initiate Enrollment of Phase 1 Trial of CER-1236 in AML Following Positive FDA Review of Manufacturing

CERo Therapeutics Holdings, Inc. Receives FDA Clearance of Second Investigational New Drug Application to Initiate Phase 1 Clinical Trial of Lead Compound CER-1236 in Solid Tumors

CERo Therapeutics Holdings, Inc. Announces Initial Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. Announces Critical Patent Application Allowances from the U.S. Patent Office Covering Company's Lead Compound CER-1236

Contracts

CERo Therapeutics, Inc. Announces Up to $8 Million Series D Financing

CERo Therapeutics Holdings, Inc. Announces Sarah Cannon Research Institute at Colorado Blood Cancer Institute as Key Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

CERo Therapeutics Holdings, Inc. to Present Poster on Lead Program, CER-1236, at the American Society of Clinical Oncology (ASCO) 2025 Annual Meeting

CERo Therapeutics Holdings, Inc. Announces TriStar Centennial Medical Center as a Clinical Trial Site for its Phase 1 Clinical Trial of CER-1236 in Acute Myeloid Leukemia

Comments

CERo Therapeutics Hldgs

Noticias

Últimas noticias sobre CERo Therapeutics Hldgs (NASDAQ:CERO) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL